Supernus Pharmaceuticals Completes Asset Acquisition
Ticker: SUPN · Form: 8-K · Filed: 2025-07-31T00:00:00.000Z
Sentiment: neutral
Topics: acquisition, assets, pharmaceuticals
TL;DR
Supernus just bought some assets from Impel. Big moves ahead?
AI Summary
On July 30, 2025, Supernus Pharmaceuticals, Inc. announced the completion of its acquisition of certain assets from Impel Pharmaceuticals Inc. for an undisclosed amount. This filing also details other events and financial statements related to the company's operations.
Why It Matters
This acquisition could expand Supernus Pharmaceuticals' product portfolio and market reach, potentially leading to future revenue growth.
Risk Assessment
Risk Level: medium — The acquisition involves undisclosed financial terms and potential integration challenges, introducing a moderate level of risk.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- Impel Pharmaceuticals Inc. (company) — Seller of acquired assets
- July 30, 2025 (date) — Date of earliest event reported
FAQ
What specific assets were acquired from Impel Pharmaceuticals Inc.?
The filing states that Supernus Pharmaceuticals, Inc. completed the acquisition of 'certain assets' from Impel Pharmaceuticals Inc., but does not specify which assets.
What was the total purchase price for the acquired assets?
The filing does not disclose the specific dollar amount paid for the acquired assets from Impel Pharmaceuticals Inc.
When did the transaction for the asset acquisition occur?
The earliest event reported in this 8-K filing related to the acquisition occurred on July 30, 2025.
What is Supernus Pharmaceuticals, Inc.'s primary business?
Supernus Pharmaceuticals, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].
Where is Supernus Pharmaceuticals, Inc. headquartered?
Supernus Pharmaceuticals, Inc. is headquartered at 9715 Key West Avenue, Rockville, MD 20850.
From the Filing
0001104659-25-072506.txt : 20250731 0001104659-25-072506.hdr.sgml : 20250731 20250731085803 ACCESSION NUMBER: 0001104659-25-072506 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250730 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250731 DATE AS OF CHANGE: 20250731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 251169656 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 tm2522014d3_8k.htm FORM 8-K false 0001356576 0001356576 2025-07-30 2025-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 30, 2025   Supernus Pharmaceuticals, Inc.  (Exact name of registrant as specified in its charter)   Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)   9715 Key West Ave Rockville MD 20850 (Address of Principal Executive Offices)     (Zip Code)   Registrant’s telephone number, including area code: ( 301 ) 838-2500   Not Applicable (Former name or former address, if changed since last report.)   Securities registered pursuant to Section 12(b) of the Exchange Act   Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Stock Market LLC   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨             Item 1.01 Entry into a Material Definitive Agreement.   As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) by Supernus Pharmaceuticals, Inc., a Delaware corporation (the “ Supernus ”), on June 16, 2025, Supernus entered into an Agreement and Plan of M